


MCGREGOR & ADLER, LLP

P.O. BOX 710509
HOUSTON, TEXAS 77271-0509

WRITER'S DIRECT DIAL
(713)-777-2321
WRITER'S DIRECT FACS.
(713)-777-6908
E. MAIL: badler1@houston.rr.com

INTELLECTUAL PROPERTY LAW
PATENT, BIOTECHNOLOGY, COMPUTER,
TRADEMARK & TRADE SECRET LAW



April 6, 2000

FACSIMILE COVER SHEET

PLEASE DELIVER TO: EXAMINER G. Bugaisky @ Art. Unit 1653

COMPANY: USPTO

FACSIMILE NUMBER: (703) 308-0294

NUMBER OF PAGES (COUNTING COVER SHEET): 6

FROM: Benjamin A. Adler, Ph.D., J.D.

MESSAGE: Please deliver the attached to Examiner Bugaisky. Examiner Bugaisky, please find enclosed the Response to the Final Office Action for USSN 08/915,659 (Our ref.: D6020). Thank you.

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of this transmittal, the information contained in this facsimile is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader is not the intended recipient or an employee or agent responsible for delivery, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please immediately notify Dr. Benjamin A. Adler at (713) 777-2321 and promptly return the facsimile. Thank you.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**APPLICANT:** O'Brien, *et al.*

§

ART UNIT: 1653

§

FILED: August 21, 1997

§

EXAMINER:

§

SERIAL NO.: 08/915,659

§

Bugaisky, G.

§

FOR: *Novel Extracellular
Serine Protease*

§

DOCKET: D6020

§

The Assistant Commissioner of Patents and Trademarks

BOX AF

Washington, DC 20231

Certificate of Facsimile Transmission

I certify that this Terminal Disclaimer was transmitted via Facsimile to Examiner G. Bugaisky at (703)308-0294 at the Patent Office on the date below.

April 6, 2000
Date

Benjamin Aaron Adler, Ph.D., J.D.

**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL
DOUBLE PATENTING REJECTION OVER A PENDING
SECOND APPLICATION UNDER 37 CFR 1.321**

The owner, Board of Trustees of the University of Arkansas of 100 percent interest in the instant application, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. Sections 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/137,944, filed on August 21, 1998. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon grantee, its successors or assigns.

04/07/2000 DWILLIA1 00000002 071185 08915659

01 FC:248

55.00 CH


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the present grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 or Title 18 of the United States code, and that such willful false statements may jeopardize the validity of the application or patent issued thereon.

The Commissioner is hereby authorized to deduct the \$55 fee required under 37 CFR §1.20(d) and any additional fees which may be required from Deposit Account No. 07-1185.

Respectfully submitted,

Date: 4/6/2000



Benjamin Aaron Adler, Ph.D., J.D.
Registration No. 35,423
Counsel for Applicant

MCGREGOR & ADLER, LLP
8011 Candle Lane
Houston, Texas 77071
(713) 777-2321
badler1@houston.rr.com